A single link to the first track to allow the export script to build the search page
  • Friday, June 17, 2016
  • 0706-000792 Poster 132 - MENINGIOMA IN THREE MALE-TO-FEMALE TRANSGENDER SUBJECTS USING OESTROGENS/PROGESTOGENS AND REVIEW OF THE LITERATURE

    June 20, 2016 8:00 AM - June 20, 2016 6:00 PM

    • Paula Valerie ter Wengel, MD, MD ;
    • Enrico Martin ;
    • Saskia Peerdeman, MD, PhD ;
    • Martin den Heijer, MD, PhD ;
    • Louis Gooren, MD, PhD

    Purpose

    Sex hormones have been proposed as a possible risk factor for the development and growth of meningiomas. Hormonal therapy plays a fundamental role in the treatment of transsexuals and needs to be continued after sex-reassignment surgery. Usually this treatment leads to no adverse events; however its impact on hormone-related tumours such as meningiomas has not yet been investigated thoroughly.

    Materials and Methods

    We searched our cohort of 2810 male-to-female transgender persons, who have been treated between 1975-2010, for patients with meningiomas. Additionally, we conducted a literature search in PubMed and Embase.

    Results

    We found three patients who developed a meningioma in male-to-female transsexuals in addition to five other that have been described in the literature.

    Conclusion

    These findings support the role of female sex hormones in the development and growth of meningiomas. This might be an underrepresentation, since there is no standard protocol for screening for meningiomas in this population and meningiomas can remain asymptomatic for several years.  We observed regression of multiple meningiomas in one of these three cases after discontinuation of hormonal treatment. 

    The decision to stop or continue cross-sex hormone therapy in these particular patients should be carefully reconsidered individually.




    Category: Endocrinology and Hormone Therapy